RVNC
Revance Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$381.02M
P/E Ratio
—
EPS
$-3.34
Beta
0.95
52W High
$0.00
52W Low
$0.00
50-Day MA
$3.39
200-Day MA
$4.16
Dividend Yield
—
Profit Margin
-71.80%
Forward P/E
—
PEG Ratio
-0.64
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Fundamentals
| Revenue (TTM) | $256.94M |
| Gross Profit (TTM) | $103.69M |
| EBITDA | $-187.62M |
| Operating Margin | -53.90% |
| Return on Equity | -2097.00% |
| Return on Assets | -24.40% |
| Revenue/Share (TTM) | $2.66 |
| Book Value | $-1.55 |
| Price-to-Book | 12.30 |
| Price-to-Sales (TTM) | 1.48 |
| EV/Revenue | 2.648 |
| EV/EBITDA | -2.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10.70% |
| Shares Outstanding | $104.39M |
| Float | $91.29M |
| % Insiders | 8.56% |
| % Institutions | 87.45% |
Data last updated: 4/9/2026